| Title： | Chinese experts‘ consensus on pancreatic cystic lesions |
| Edition： | Adapted |
| Classification： | Experts consensus |
| Field： | Diagnosis |
| Countries and regions： | China |
| Guidelines users： | This consensus is applicable to clinicians, nurses, technicians from departments of gastroenterology, pancreatic surgery and medical imaging who are engaging in pancreatic diseases and relevant teaching and scientific research staffs. |
| Evidence classification method： | The grading of recommendations assessment, development, and evaluation (grade) system is used to evaluate the evidence quality and recommendation strength. High = Further research is unlikely to change our confidence in the estimate of effect. Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low = Any estimate of effect is very uncertain. |
| Development unit： | The First Affiliated Hospital of Naval Medical University |
| Registration time: | 2022-05-02 |
| Registration number： | IPGRP-2022CN252 |
| Purpose of the guideline: | Pancreatic cystic neoplasm (PCN) include intraductal papillary mucinous tumor (IPMN), mucinous cystadenoma (MCN), serous cystadenoma (SCN) and other rare cystic lesions. The biological features and risk of malignant transformation of the PCNs vary. With the development of medical imaging, the detection rate of PCNs is increasing. Therefore, optimizing the follow-up strategy of PCN to assess its malignant transformation probability and surgical risk has become an increasingly important clinical issue. |
Latest registration
